



Supporting Information

© Wiley-VCH 2008

69451 Weinheim, Germany

Supporting Information

Azadipeptide Nitriles – Highly Potent and Proteolytically Stable Inhibitors of Papain-like Cysteine Proteases

Reik Löser, Maxim Frizler, Klaus Schilling, and Michael Gütschow

Content

Figure S1. Monitoring of the human cathepsin L-catalyzed substrate hydrolysis in the presence of the azadipeptide nitrile **6** and plot of the rates versus concentrations of **6**.

Figure S2. Monitoring of the human cathepsin L-catalyzed substrate hydrolysis in the presence of the dipeptide nitrile **12** and plot of the rates versus concentrations of **12**.

Figure S3. Reactivation of cathepsin L and papain, inhibited by the azadipeptide nitrile **6**.

Figure S4. Time courses of the chymotrypsin-catalyzed degradation of the azadipeptide nitrile **6** and the dipeptide nitriles **12** and **14**.

Figure S5. Time course of the chymotrypsin-catalyzed cleavage of **6** to form Z-Phe-OH.

Scheme S1. Synthesis of hydrazides **1-3** and azadipeptide nitriles **6** and **7**.


Scheme S2. Synthesis of azadipeptide nitriles **8-10**.

Scheme S3. Synthesis of the dipeptide nitriles **12-14**.

Experimental Section

References

A)



B)





Figure S1. (A) Congruent with Figure 1 of the publication. Monitoring of the human cathepsin L-catalyzed hydrolysis of Z-Phe-Arg-NHMec (10 μ M) in the presence of increasing concentrations of the azadipeptide nitrile **6** (●, 0; ●, 3 nM; ●, 4 nM; ●, 8 nM; ●, 9 nM; ●, 10 nM; ●, 20 nM; ●, 30 nM; ●, 50 nM; ●, 100 nM). The reaction (100 mM sodium phosphate pH 6.0, 100 mM NaCl, 5 mM EDTA, 0.01 % Brij 35, 25 μ M DTT, 1 % DMSO, 37 °C) was initiated by addition of the enzyme. Fluorescence emission at 440 nm (I = fluorescence intensity) was measured after excitation at 360 nm. Fluorescence units (FU) were corrected for background fluorescence. (B) Plot of the rates of hydrolysis of Z-Phe-Arg-NHMec versus concentrations of **6**. Non-linear regression gave an apparent inhibition constant $K_i' = (1+[S]/K_m) K_i = 0.60 \pm 0.08$ nM. Inset: Plot of the k_{obs} values versus concentrations of **6**. The linear dependence indicates a one-step mechanism for the enzyme-inhibitor interaction. Linear regression gave an apparent second-order rate constant $k_{\text{on}}' = k_{\text{on}} / (1 + [S]/K_m) = (910 \pm 10) \times 10^3 \text{ M}^{-1}\text{s}^{-1}$. From the corresponding k_{on} value, a first-order rate constant $k_{\text{off}} = k_{\text{on}} K_i = (0.54 \pm 0.07) \times 10^{-3} \text{ s}^{-1}$ was calculated.

A)



B)





Figure S2. (A) Monitoring of the human cathepsin L-catalyzed hydrolysis of Z-Phe-Arg-NHMec (10 μ M) in the presence of increasing concentrations of the dipeptide nitrile **12** (●, 0; ●, 1 μ M; ●, 2 μ M; ●, 3 μ M; ●, 4 μ M; ●, 5 μ M; ●, 7 μ M; ●, 10 μ M). The reaction (100 mM sodium phosphate pH 6.0, 100 mM NaCl, 5 mM EDTA, 0.01 % Brij 35, 25 μ M DTT, 1 % DMSO, 37 °C) was initiated by addition of the enzyme. Fluorescence emission at 440 nm (I = fluorescence intensity) was measured after excitation at 360 nm. Fluorescence units (FU) were corrected for background fluorescence. (B) Plot of the rates of hydrolysis of Z-Phe-Arg-NHMec versus concentrations of **12**. Non-linear regression gave an apparent inhibition constant $K_i' = (1 + [S] / K_m) K_i = 2.3 \pm 0.2 \mu\text{M}$.

A)



B)





Figure S3. Reactivation of cathepsin L and papain, respectively, inhibited by the azadipeptide nitrile **6**. Fluorescence emission at 440 nm (I = fluorescence intensity) was measured after excitation at 360 nm. Fluorescence units (FU) were corrected for background fluorescence. (A) Reactivation of cathepsin L. The cathepsin L-catalyzed hydrolysis of Z-Phe-Arg-NHMec (10 μ M) was monitored in 0.1 M sodium phosphate pH 6.0, 5 mM EDTA, 0.1 M sodium chloride and 0.01 % Brij 35 with final concentrations of 10 pg/mL cathepsin L, 20 pM **6**, 1.02 % DMSO, 0.5 μ M DTT. In the reactivation experiment, cathepsin L (1 ng/mL) was preincubated with **6** (2 nM) for 30 min at 25 °C. In the control experiment, the preincubation was done in the absence of the inhibitor. The initial rates were clearly different, 1.3 ± 0.1 FU min^{-1} and 9.6 ± 0.1 FU min^{-1} for reactivation (●) and control (●), respectively. The final rates were similar, 2.2 ± 0.1 FU min^{-1} and 1.6 ± 0.1 FU min^{-1} for reactivation and control, respectively. The first-order rate constant of reactivation $k_{\text{obs}} = (1.4 \pm 0.1) \times 10^{-3} \text{ s}^{-1}$ was in the same range as the k_{off} value ($0.54 \times 10^{-3} \text{ s}^{-1}$) calculated from the data of the association experiments (Figure S1). (B) Reactivation of papain. The papain-catalyzed hydrolysis of Z-Phe-Arg-NHMec (10 μ M) was monitored in 0.1 M sodium phosphate pH 6.5, 2.5 mM EDTA with final concentrations of 1 ng/mL papain, 50 pM **6**, 1.4 % DMSO, 1.5 μ M DTT. In the reactivation experiment, papain (0.2 μ g/mL) was preincubated with **6** (10 nM) for 30 min at 25 °C. In the control experiment, the preincubation was done in the absence of the inhibitor. The initial rates were clearly different, 0.62 ± 0.01 FU min^{-1} and 5.8 ± 0.1 FU min^{-1} for reactivation (●) and control (●), respectively. The final rates were similar, 1.3 ± 0.1 FU min^{-1} and 0.95 ± 0.01 FU min^{-1} for reactivation and control, respectively. The first-order rate constant of reactivation $k_{\text{obs}} = (1.1 \pm 0.1) \times 10^{-3} \text{ s}^{-1}$ was in the same range as the k_{off} value ($0.40 \times 10^{-3} \text{ s}^{-1}$) calculated from the data of the association experiments.

(A)



(B)




Figure S4. (A) Congruent with Figure 2 of the publication. Time course of the chymotrypsin-catalyzed degradation of the azadipeptide nitrile **6** (●) and the dipeptide nitriles **12** (●) and **14** (●). Mixtures of the corresponding nitrile (600 μM) and chymotrypsin (100 $\mu\text{g/mL}$) in 20 mM Tris-HCl pH 8.4, 150 mM NaCl, 10 % acetonitrile were kept at 25 °C and 20 μL aliquots were injected into the HPLC. The pseudo first-order rate constant for the decay of **12** obtained by using the equation $c = c_0 \exp(-kt)$ was $0.015 \pm 0.001 \text{ min}^{-1}$, which corresponds to a half-life of 45 min. Linear regression of the data points for the hydrolysis of **14** gave an initial rate of $0.48 \pm 0.03 \mu\text{M min}^{-1}$, which corresponds to a half-life of 14 h, assuming a pseudo first-order kinetics. (B) Time course of the chymotrypsin-catalyzed degradation of **12** (●) to form Z-Phe-OH (●). From the time course of the chymotrypsin-catalyzed hydrolysis of **12** and from the formation of Z-Phe-OH the same pseudo first-order rate constants of $0.015 \pm 0.001 \text{ min}^{-1}$ were calculated by using the equation $c = c_0 \exp(-kt)$. This corresponds to a half-life of 45 min. The control reaction in the absence of chymotrypsin is also shown (●).







Figure S5. Time course of the chymotrypsin-catalyzed cleavage of **6** (●) to form Z-Phe-OH (●). A mixture of **6** (600 μM) and chymotrypsin (1000 $\mu\text{g}/\text{mL}$) in 20 mM Tris-HCl pH 8.4, 150 mM NaCl, 10 % acetonitrile was kept at 25 $^{\circ}\text{C}$ and 20 μL aliquots were injected into the HPLC. Non-linear regression of the data points for the hydrolysis of **6** and the formation of Z-Phe-OH according to equation (3) gave steady-state rates of $0.57 \pm 0.01 \mu\text{M min}^{-1}$ and $0.51 \pm 0.01 \mu\text{M min}^{-1}$, respectively.



Scheme S1. The lower part is congruent with Scheme 2 of the publication. Synthesis of hydrazides **1-3** and azadipeptide nitriles **6** and **7**. Reagents and conditions: a) HCl/MeOH, reflux; b) $\text{N}_2\text{H}_4 \times \text{H}_2\text{O}$, MeOH, RT; c) BrCN, NaOAc, MeOH, RT; d) 1. *N*-methylmorpholine, isobutylchloroformate, THF, 2. methylhydrazine, -25°C to RT; e) 1. *N*-methylmorpholine, isobutylchloroformate, THF, 2. dimethylhydrazine dihydrochloride, H_2O , 1 M NaOH, -25°C to RT.



Scheme S2. Congruent with Scheme 3 of the publication. Synthesis of azadipeptide nitriles **8-10**. Reagents and conditions: a) RCHO, THF, RT; b) 1. $(\text{CH}_3)_2\text{NH} \times \text{BH}_3$, *p*TsOH, CH_2Cl_2 , 4 °C; 2. 1.5 M NaOH, RT; c) BrCN, NaOAc, MeOH, RT.



Scheme S3. Synthesis of the dipeptide nitriles **12-14**. Reagents and conditions: a) 1. *N*-methylmorpholine, isobutylchloroformate, THF, 2. 25 % NH_3 , $-25\text{ }^\circ\text{C}$ to RT; b) HCl/ethyl acetate, RT; c) 1. *Z*-Phe-OH, *N*-methylmorpholine, isobutylchloroformate, THF, 2. H_2O , 1 M NaOH, $-25\text{ }^\circ\text{C}$ to RT; d) $(\text{ClCN})_3$, DMF, RT; e) 1. *N*-methylmorpholine, isobutylchloroformate, THF, 2. *N*-methylaminoacetonitrile hydrochloride, H_2O , 1 M NaOH, $-25\text{ }^\circ\text{C}$ to RT.

Experimental Section

General Methods and Materials. Melting points were determined on a Büchi 510 oil bath apparatus and are not corrected. Thin layer chromatography was performed on Merck aluminium sheets. Preparative column chromatography was performed on silica gel 60 (Fluka) 70-230 mesh. Optical rotations were determined on a Perkin-Elmer 241 polarimeter. ^1H NMR spectra (500 MHz) and ^{13}C NMR spectra (125 MHz) were recorded on a Bruker Avance 500. Mass spectra were obtained on an API 2000 spectrometer from Applied Biosystems (ESI, sprayed from a 10^{-5} M solution in 2mM $\text{NH}_4\text{OAc}/\text{MeOH}$ 1:1; volumetric flow rate 10 $\mu\text{L}/\text{min}$) and on a A.E.I. MS-50 spectrometer (EI, 70 eV). IR spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer. Enzymatic activity of papain and cathepsins was measured spectrophotometrically at a Varian Cary Bio 50 UV/Vis spectrophotometer or fluorometrically at a Perkin Elmer luminescence spectrometer LS 50 B, respectively. Reactivation experiments were performed at a Perkin Elmer luminescence spectrometer LS 55. Analytical HPLC as performed on a Dionex HPLC system, equipped with a P580 A LPG gradient pump, a manual injection valve (20 μL), an UV/VIS detector UVD 170, and a Hypersil NC-04 column (RP-18, 5 μm , 250 \times 4.60 mm). Papain was purchased from Sigma-Aldrich, Steinheim, Germany. Recombinant human cathepsin L, His Tag, and recombinant human cathepsin S were purchased from Calbiochem, Darmstadt, Germany. Recombinant human cathepsin K (expressed in *Pichia pastoris*) was a gift of D. Brömme.^[1] α -Chymotrypsin (bovine pancreas) was purchased from Fluka, Buchs, Switzerland. The substrates, Z-Phe-Arg-NHNp, Z-Phe-Arg-NHMec, Z-Val-Val-Arg-NHMec, Z-Leu-Arg-NHMec, and Suc-Ala-Ala-Pro-Phe-NHNp were from Bachem, Bubendorf, Switzerland. The amino acid derivatives were purchased from Novabiochem, Läufelfingen, Switzerland; Bachem, Bubendorf, Switzerland; and Fluka, Deisenhofen, Germany. DTT (= (\pm)-*threo*-2,3-dihydroxy-1,4-butanedithiol), Brij 35 P and Triton X-100 were obtained from Fluka, Deisenhofen, Germany; CHAPS (= 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) was from Sigma, Germany. Mathematical data analyses were done with the programs Grafit 4 (Erithacus Software) and GraphPad Prism 4 (GraphPad Software). *N*-(Benzyloxycarbonyl)-phenylalanyl-glycine-nitrile (**11**) was prepared as described.^[2]

Inhibition Assays. Cathepsins. Enzyme activities were calculated from kinetic measurements performed by fluorimetric detection of the product AMC at 37 °C in a stirred cuvette. The wavelengths for excitation and emission were 360 nm and 440 nm, respectively. The reaction volume of the assay was 2 mL. To assay cathepsin L, Z-Phe-Arg-NHMec was

used as substrate at a concentration of $10 \mu\text{M}$ ($= 7.07 K_m$)^[3] in 100 mM sodium phosphate pH 6.0, 100 mM NaCl, 5 mM EDTA, 0.01 % Brij 35, 25 μM DTT and 1 % DMSO. For cathepsin S, Z-Val-Val-Arg-NHMec was chosen as substrate at a concentration of $40 \mu\text{M}$ ($= 2.08 K_m$)^[2] in 50 mM potassium phosphate pH 6.5, 50 mM NaCl, 2 mM EDTA, 0.01 % Triton X-100, 25 μM DTT and 1 % DMSO. In the cathepsin K assay, Z-Leu-Arg-NHMec was used as substrate at a concentration of $20 \mu\text{M}$ ($= 3.23 K_m$)^[2] in 100 mM sodium citrate pH 5.0, 100 mM NaCl, 1 mM EDTA, 0.01 % CHAPS, 25 μM DTT and 1 % DMSO. Stock solutions of the substrates and the inhibitors were prepared in DMSO. The enzyme dilutions were daily prepared from a stock with the corresponding assay medium without DMSO, containing 5 mM DTT (the complete amount of DTT required for the final concentration noted above), and kept on ice. After thermal equilibration, 10 μL of the enzyme solution were added and product formation was monitored over 5 min. The inhibition constants were calculated from measurements at ten to twelve different inhibitor concentrations and two or three controls in the absence of the inhibitor.

Papain. Enzyme activities were determined by spectrophotometric detection of the product *p*-nitroaniline (pNA) at 25 °C in a multi-cell holder (final volume 1 mL) at a wavelength of 405 nm. A 4 mM stock solution of the chromogenic substrate Z-Phe-Arg-NHNp was prepared in DMSO, the final concentration was $200 \mu\text{M}$ ($= 0.207 K_m$)^[2]. The assay medium was 0.1 M sodium phosphate pH 6.5, 2.5 mM EDTA, 300 μM DTT and 12 % DMSO. Stock solutions of the inhibitors were prepared in DMSO. In the absence of inhibitor, 70 μL of DMSO were added to the cuvette. A papain stock solution was prepared in 1 mM HCl. For daily activation, the papain stock solution was diluted 1:100 in 0.1 M sodium phosphate pH 6.5, 2.5 mM EDTA, 15 mM DTT and incubated at 25 °C for 1 h. The activated enzyme was kept on ice. After thermal equilibration, the reaction was initiated by addition of the enzyme (20 μL), its final concentration catalyzed the conversion of the substrate with a rate of 1-2 $\mu\text{M}/\text{min}$. Progress curves were monitored over 10 min. Rates were determined for seven or eight different inhibitor concentrations in duplicate and two measurements in the absence of the inhibitor.

Determination of Kinetic Parameters for the Inhibition of Cysteine Proteases. The progress curves of the cysteine protease-catalyzed reactions in the presence of the dipeptide nitriles **11-14** were linear. The apparent inhibition constant K_i' was determined by fitting

$$v = v_0/(1+[I]/K_i') \quad (1)$$

to the experimental data, where v is the rate, v_0 is the rate in absence of inhibitor, and $[I]$ is the inhibitor concentration. The true inhibition constant K_i was calculated by correction of K_i' according to

$$K_i = K_i' / (1 + [S]/K_m) \quad (2)$$

where $[S]$ is the substrate concentration and K_m is the Michaelis constant.

Progress curves of the reactions of cysteine proteases in the presence of azadipeptide nitriles **6-10** were analyzed by non-linear regression using equation (3),

$$[P] = v_s t + (v_i - v_s)(1 - \exp(-k_{obs}t)) / k_{obs} + d \quad (3)$$

where $[P]$ is the product concentration, v_s is the steady state rate, v_i is the initial rate, k_{obs} is the observed pseudo first-order rate constant and d is the offset. To obtain K_i' values, steady state rates together with the rate in the absence of the inhibitor were fitted according to equation (1), and K_i was calculated from equation (2). The apparent second-order rate constant k_{on}' was obtained by linear regression according to equation (4).

$$k_{obs} = k_{on}' [I] + k_{off} \quad (4)$$

The true rate constant k_{on} was calculated by correction of k_{on}' according to equation (5).

$$k_{on} = k_{on}' (1 + [S]/K_m) \quad (5)$$

The first-order rate constant k_{off} for the dissociation of the enzyme-inhibitor complex was calculated according to equation (6).

$$k_{off} = k_{on} K_i \quad (6)$$

Reactivation of Cathepsin L. Twenty microliters of a solution of **6** (100 nM in DMSO) were added to 970 μ L of 0.1 M sodium phosphate pH 6.0, 5 mM EDTA, 0.1 M sodium chloride and 0.01 % Brij 35. A cathepsin L stock solution (50 μ g/mL in 20 mM sodium acetate pH 5.0, 100 mM sodium chloride, 10 mM trehalose, 1 mM EDTA and 50 % glycerol) was diluted 1:100 in 0.1 M sodium phosphate pH 6.0, 5 mM EDTA, 0.1 M sodium chloride,

0.01 % Brij 35, 5 mM DTT and kept at 25 °C for 30 min. After activation, the enzyme solution was diluted 1:5 with the same buffer. Ten microliters of the resulting enzyme dilution were added to the solution of **6**. After preincubation for 30 min at 25 °C, 10 μ L of the solution were added into a cuvette containing 980 μ L of 0.1 M sodium phosphate pH 6.0, 5 mM EDTA, 0.1 M sodium chloride and 0.01 % Brij 35. The reaction was immediately initiated by addition of 10 μ L of a solution of Z-Phe-Arg-NHMec (1 mM in DMSO). The reaction volume of the reactivation experiment was 1 mL. Final concentrations were as follows, 10 pg/mL of cathepsin L, 10 μ M Z-Phe-Arg-NHMec, 20 pM of **6**, 1.02 % DMSO and 0.5 μ M DTT. The cathepsin L activity was followed for 70 min by fluorimetric detection of the product AMC. The wavelengths for excitation and emission were 360 nm and 490 nm, respectively. In the control measurement, the solution of **6** was replaced by DMSO. The reactivation was analyzed by fitting the data to equation (3) to determine k_{obs} , the first-order rate constant of reactivation, v_i , the initial rate, and v_s , the final rate. The control reaction was analyzed by fitting the data to equation (3) to determine v_i , the initial rate, and v_s , the final rate.

Reactivation of Papain. Ten microliters of a solution of **6** (1 μ M in DMSO) were added to 900 μ L of 0.1 M sodium phosphate pH 6.5, 2.5 mM EDTA and 70 μ L of DMSO. A papain stock solution (1 mg/mL in 1 mM HCl) was diluted 1:100 in 0.1 M sodium phosphate pH 6.5, 2.5 mM EDTA, 15 mM DTT and kept at 25 °C for 1 h. Twenty microliters of the activated enzyme solution were added to the solution of **6**. After preincubation for 30 min at 25 °C, 5 μ L of the solution were added into a cuvette containing 985 μ L of 0.1 M sodium phosphate pH 6.5, 2.5 mM EDTA. The reaction was immediately initiated by addition of 10 μ L of a solution of Z-Phe-Arg-NHMec (1 mM in DMSO). The reaction volume of the reactivation experiment was 1 mL. Final concentrations were as follows, 1 ng/mL of papain, 10 μ M Z-Phe-Arg-NHMec, 50 pM of **6**, 1.4 % DMSO, 1.5 μ M DTT. The papain activity was followed for 100 min by fluorimetric detection of the product AMC as described above. In the control measurement, the solution of **6** was replaced by DMSO. The papain reactivation experiment was analyzed by the same mathematical method used for the cathepsin L reactivation experiment.


Inhibition of Chymotrypsin. Chymotrypsin activity was determined in the presence of compounds **6**, **12**, and **14**. The assay was performed at 25 °C in a multi-cell holder at a wavelength of 405 nm in the presence of 9 % acetonitrile and 1 % DMSO (final volume 1 mL). The assay buffer was 20 mM Tris-HCl pH 8.4, 150 mM NaCl. A 20 mM stock solution of the chromogenic substrate Suc-Ala-Ala-Pro-Phe-NHNp was prepared in DMSO, the final concentration was 200 μ M. Stock solutions of the inhibitors were prepared in acetonitrile. In

the absence of inhibitor, 90 μL of acetonitrile were added to the cuvette. A chymotrypsin solution (10 $\mu\text{g}/\text{ml}$) was prepared in 1 mM HCl and diluted with assay buffer. The reaction was initiated by addition of 40 μL of a chymotrypsin solution (250 ng/mL). Progress curves were monitored over 12 min. Rates were determined in duplicate for six different inhibitor concentrations (compound **6**) or at 600 μM inhibitor concentration (compounds **12** and **14**).

Analysis of the Proteolytic Stability of Selected Inhibitors. Separate solutions of compounds **6**, **12**, **14**, and Z-Phe-OH in 20 mM Tris-HCl pH 8.4, 150 mM NaCl, 10 % acetonitrile were prepared at the following concentrations, 600, 500, 400, 300, 200, 100, 50, 25 μM . Solutions of compounds **6**, **12**, and Z-Phe-OH were kept in glass vials, whereas those of **14** were kept in quartz vials. Aliquots were injected into the HPLC, and isocratic elution conditions (water : acetonitrile : trifluoroacetic acid, 1 : 1 : 0.0016, v/v) and a flow rate of 1.5 mL/min were used. Detection was performed at a wavelength of 214 nm. Calibration curves were generated and linear regression analysis was carried to give the following slopes and standard errors, $0.0507 \pm 0.0006 \text{ mAU min } \mu\text{M}^{-1}$ (**6**), $0.0436 \pm 0.0004 \text{ mAU min } \mu\text{M}^{-1}$ (**12**), $0.0606 \pm 0.0012 \text{ mAU min } \mu\text{M}^{-1}$ (**14**), $0.0394 \pm 0.0010 \text{ mAU min } \mu\text{M}^{-1}$ (Z-Phe-OH). The compounds had the following retention times, 5.2 min (**6**), 4.3 min (**12**), 6.0 min (**14**), 3.7 min (Z-Phe-OH).


To determine the proteolytic stability towards chymotrypsin, to 800 μL of 20 mM Tris-HCl pH 8.4, 150 mM NaCl, 40 μL of acetonitrile and 60 μL of a 10 mM solution of the compounds **6**, **12** and **14** in acetonitrile were added. At 25 $^{\circ}\text{C}$, solutions of **6** and **12** were kept in glass vials, whereas those of **14** was kept in a quartz vial. Reactions were initiated by addition of 100 μL of 1 mg/mL solution of chymotrypsin. Final concentrations were as follows, 600 μM of each compound, 10 % acetonitrile, 100 $\mu\text{g}/\text{mL}$ chymotrypsin. Aliquots were injected into the HPLC in 15 min intervals over 195 min. The HPLC conditions noted above were applied. In a second experiment, incubations of **6** were performed similarly, with a final chymotrypsin concentration of 1 mg/mL . Aliquots were injected in 30 min intervals over 360 min. The chymotryptic cleavage was analyzed by using the calibration curves.

***N*-(Benzyloxycarbonyl)-phenylalanine methyl ester**




On an ice-bath, acetyl chloride (0.62 mL, 8.7 mmol) was dropped to MeOH (10 mL). After 15 min, *N*-(benzyloxycarbonyl)-phenylalanine (2.0 g, 6.7 mmol) was added in portions. The solution was refluxed for 2 h and stirred for additional 2 h at room temperature. The solvent was evaporated, and the residue was dissolved in ethyl acetate (60 mL), washed with 10 % NaHSO₄ (10 mL), H₂O (10 mL), sat. NaHCO₃ (2 × 10 mL) and brine (10 mL) and dried (Na₂SO₄). The solvent was removed under reduced pressure to obtain *N*-(benzyloxycarbonyl)-phenylalanine methyl ester^[4] (1.95 g, 93 %) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 3.07 (dd, ²*J* = 13.9 Hz, ³*J* = 6.0 Hz, 1H, PhCH₂CH), 3.13 (dd, ²*J* = 13.9 Hz, ³*J* = 5.7 Hz, 1H, PhCH₂CH), 3.70 (s, 3H, OCH₃), 4.62-4.68 (m, 1H, NHCHCO), 5.06 (d, ²*J* = 12.3 Hz, 1H, PhCH₂CH), 5.10 (d, ²*J* = 12.3 Hz, 1H, PhCH₂CH), 5.22 (d, ³*J* = 7.9 Hz, 1H, NHCHCO), 7.06-7.10 (m, 2H, 2'-H, 6'-H), 7.20-7.37 (m, 8H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 38.19 (PhCH₂CH), 52.28 (OCH₃), 54.77 (NHCHCO), 66.93 (PhCH₂O), 127.11 (C-4'), 128.05 (C-2'', C-6''), 128.15 (C-4''), 128.49, 128.57, 129.23 (C-2', C-6', C-3', C-5', C-3'', C-5''), 135.66, 136.22 (C-1', C-1''), 155.59 (OCONH), 171.93 (CHCOOCH₃). C₁₈H₁₉NO₄ (313.35 g/mol).

***N*-(Benzyloxycarbonyl)-phenylalanine hydrazide (1)**




Hydrazine hydrate (1.51 mL, 31.1 mmol) was added to a solution of *N*-(benzyloxycarbonyl)-phenylalanine methyl ester (1.90 g, 6.1 mmol) in MeOH (10 mL). A white product precipitated within 20 min. H₂O (20 ml) was added after 1 h, the precipitate was isolated by suction filtration, washed with H₂O, and dried in a desiccator over P₄O₁₀ to yield **1** (1.83 g, 96 %): mp 164-165 °C (lit.^[5] mp 165 °C); ¹H NMR (500 MHz, CDCl₃) δ 2.99-3.09 (m, 2H, PhCH₂CH), 3.40 (br s, 2H, NHNH₂), 4.30-4.39 (m, 1H, NHCHCO), 5.03 (d, ²J = 12.3 Hz, 1H, PhCHHO), 5.06 (d, ²J = 12.6 Hz, 1H, PhCHHO), 5.33 (d, ³J = 6.0 Hz, 1H, NHCHCO), 7.10-7.17 (m, 3H, 2'-H, 6'-H, CONHNH₂), 7.20-7.36 (m, 8H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃): δ 38.41 (PhCH₂CH), 55.09 (NHCHCO), 67.23 (PhCH₂O), 127.22 (C-4'), 128.09 (C-2'', C-6''), 128.31 (C-4''), 128.57, 128.81, 129.14 (C-2', C-6', C-3', C-5', C-3'', C-5''), 135.93, 136.04 (C-1', C-1''), 155.91 (OCONH), 171.53 (CHCONHNH₂). Anal. C₁₇H₁₉N₃O₃ (313.35 g/mol) calcd C 65.16, H 6.11, N 13.41; found C 65.04, H 6.32, N 13.39.

***N*-(Benzyloxycarbonyl)-phenylalanine 2-methylhydrazide (2)**




N-(Benzyloxycarbonyl)-phenylalanine (2.0 g, 6.68 mmol) was dissolved in THF (15 mL) and cooled to $-25\text{ }^{\circ}\text{C}$. To the stirred solution, *N*-methylmorpholine (0.74 mL, 6.68 mmol) and isobutylchloroformate (0.88 mL, 6.68 mmol) were added consecutively. After precipitation of *N*-methylmorpholine hydrochloride, methyl hydrazine (1.78 mL, 33.4 mol) was added and the mixture was allowed to warm to room temperature within 30 min. It was stirred for additional 90 min, and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (60 mL) and the solution was washed with H_2O ($1 \times 15\text{ mL}$), sat. NaHCO_3 ($1 \times 15\text{ mL}$) and brine ($1 \times 15\text{ mL}$). The solvent was dried (Na_2SO_4) and evaporated. The resulting mixture of the regioisomers **2** and **3** was fractionated on silica gel using $\text{CH}_2\text{Cl}_2 / \text{MeOH}$ (40:1) as eluent. Compound **2** (0.54 g, 29 %) was obtained as the second main fraction: mp 138-139 $^{\circ}\text{C}$ (lit.^[6] mp 138-140 $^{\circ}\text{C}$); ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 2.39 (s, 3H, CH_3NH), 2.79 (dd, $^2J = 13.6\text{ Hz}$, $^3J = 9.8\text{ Hz}$, 1H, PhCHHCH), 2.92 (dd, $^2J = 13.6\text{ Hz}$, $^3J = 5.0\text{ Hz}$, 1H, PhCHHCH), 3.30 (br s, 1H, NHNHCH_3), 4.12-4.20 (m, 1H, NHCHCO), 4.94 (s, 2H, PhCH_2CO), 7.15-7.35 (m, 10H, H_{arom}), 7.52 (d, $^3J = 8.5\text{ Hz}$, 1H, NHCHCO), 8.46 (s, 1H, CONHNH); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 37.74, 38.16 (PhCH_2CH , CH_3NH), 54.97 (NHCHCO), 65.37 (PhCH_2O), 126.43 (C-4'), 127.59 (C-2'', C-6''), 127.80 (C-4''), 128.18, 128.40, 129.35 (C-2', C-6', C-3', C-5', C-3'', C-5''), 137.16, 137.89 (C-1', C-1''), 155.86 (OCONH), 170.06 (CHCONHNH). Anal. $\text{C}_{18}\text{H}_{21}\text{N}_3\text{O}_3$ (327.38 g/mol) calcd C 66.04, H 6.47, N 12.84; found C 66.14, H 6.74, N 12.71.

***N*-(Benzyloxycarbonyl)-phenylalanine 1-methylhydrazide (3)**




Compound **3** was prepared by the aforementioned procedure and was isolated as the first main fraction of the column chromatography (1.78 g, 54 %): mp 121-122 °C (lit.^[6] mp 122-124 °C); ¹H NMR (500 MHz, CDCl₃) mixture of *cis/trans* rotamers δ 2.85-3.01 (m), 3.04 (s) (Σ 5H, PhCH₂CH, CH₃N), 3.87 (br s, 2H, CONNH₂), 4.75-4.85 (m), 4.97-5.09 (m), 5.39-5.60 (m), 5.79 (d, ³J = 8.5 Hz) (Σ 4H, NHCHCO, PhCH₂O, NHCHCO), 7.05-7.35 (m, 10 H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) mixture of *cis/trans* rotamers, w = weak (refers to minor rotamer), i = intensive (refers to major rotamer) δ 37.42 (w), 38.56 (i) (PhCH₂CH), 39.47 (w), 39.95 (i) (CH₃N), 51.39 (i), 52.10 (w) (NHCHCO), 66.60 (i), 66.94 (w) (PhCH₂O), 126.72 (i), 127.16 (w) (C-4'), 127.91 (w), 127.96 (i) (C-2'', C-6''), 128.11 (w), 128.18 (i), 128.42 (i), 128.47 (w) (C-2', C-6', C-3', C-5'), 128.64 (i), 128.70 (w) (C-4''), 129.28 (w), 129.45 (i) (C-3'', C-5''), 135.74 (w), 136.18 (w), 136.51 (i), 136.82 (i) (C-1', C-1''), 155.65 (w), 155.70 (i) (OCONH) 169.80 (w), 173.49 (i) (CHCONNH₂). Anal. C₁₈H₂₁N₃O₃ (327.38 g/mol) calcd C 66.04, H 6.47, N 12.84; found C 66.24, H 6.81, N 12.53.

***N*-(Benzyloxycarbonyl)-phenylalanine 1,2-dimethylhydrazide (4)**




N-(Benzyloxycarbonyl)-phenylalanine (2.0 g, 6.68 mmol) was dissolved in THF (15 mL) and cooled to $-25\text{ }^{\circ}\text{C}$. To the stirred solution, *N*-methylmorpholine (0.74 mL, 6.68 mmol) and isobutylchloroformate (0.88 mL, 6.68 mmol) were added consecutively. 1,2-Dimethylhydrazine dihydrochloride (4.44 g, 33.4 mmol) was dissolved in H_2O (1 mL), and 5 M NaOH (13.4 mL) was added under ice-cooling. This solution was given to the reaction mixture when the precipitation of *N*-methylmorpholine hydrochloride occurred. It was allowed to warm to room temperature within 30 min and stirred for additional 90 min. After evaporation of the solvent, the resulting aqueous residue was extracted with ethyl acetate ($1 \times 40\text{ mL}$, $3 \times 10\text{ mL}$). The combined organic layers were washed with H_2O ($1 \times 15\text{ mL}$), sat. NaHCO_3 ($2 \times 15\text{ mL}$), H_2O ($1 \times 15\text{ mL}$), and brine ($1 \times 15\text{ mL}$). The solvent was dried (Na_2SO_4) and evaporated to obtain a colorless oil which slowly solidified at room temperature (2.22 g, 97 %): mp $65\text{-}70\text{ }^{\circ}\text{C}$; ^1H NMR (500 MHz, CDCl_3) δ 2.45 (s, 3H, CH_3NH), 2.90 (dd, $^2J = 13.3\text{ Hz}$, $^3J = 6.6\text{ Hz}$, PhCHHCH), 2.98 (dd, $^2J = 13.6\text{ Hz}$, $^3J = 7.0\text{ Hz}$, 1H, PhCHHCH), 3.01 (s, 3H, CH_3N), 5.01 (d, $^2J = 12.6\text{ Hz}$, 1H, PhCHHO), 5.06 (d, $^2J = 12.3\text{ Hz}$, 1H, PhCHHO), 5.40-5.53 (m, 2H, NHCHCO , NHCHCO), 7.11-7.37 (m, 10H, H_{arom}); ^{13}C NMR (125 MHz, CDCl_3) δ 31.75, 35.39, 39.62 (CH_3NH , PhCH_2CH , CH_3N), 51.51 (NHCHCO), 66.57 (PhCH_2O), 126.66 (C-4'), 127.91 (C-2'', C-6''), 127.95 (C-4''), 128.21, 128.42, 129.46 (C-2', C-6', C-3', C-5', C-3'', C-5''), 136.51, 136.84 (C-1', C-1''), 155.72 (OCONH), 173.69 (OCONNH). Anal. $\text{C}_{19}\text{H}_{23}\text{N}_3\text{O}_3$ (341.40 g/mol) calcd C 66.84, H 6.79, N 12.31; found C 66.93, H 6.83, N 12.14.

***N*-(Benzyloxycarbonyl)-leucine 1,2-dimethylhydrazide (5)**




In a separating funnel, *N*-(benzyloxycarbonyl)-leucine dicyclohexylamine salt (2.0 g, 4.4 mmol) was suspended in ethyl acetate (40 mL), and ice-cold 1 M H₂SO₄ (12 mL) was added. The aqueous layer was diluted with H₂O (15 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with H₂O (1 × 15 mL), brine (1 × 10 mL), dried (Na₂SO₄) and evaporated. The obtained *N*-(benzyloxycarbonyl)-leucine (1.3 g, 4.90 mmol) was dissolved in THF (10 mL) and cooled to -25 °C. To the stirred solution, *N*-methylmorpholine (0.54 mL, 4.90 mmol) and isobutylchloroformate (0.64 mL, 4.90 mmol) were added consecutively. 1,2-Dimethylhydrazine dihydrochloride (3.26 g, 24.5 mmol) was dissolved in H₂O (1 mL), and 5 M NaOH (10 mL) was added under ice-cooling. This solution was given to the reaction mixture when the precipitation of *N*-methylmorpholine hydrochloride occurred. It was allowed to warm to room temperature within 30 min and stirred for additional 90 min. After evaporation of the solvent, the residue was suspended in H₂O (5 mL) and extracted with ethyl acetate (1 × 30 mL, 3 × 10 mL). The combined organic layers were washed with H₂O (2 × 15 mL), sat. NaHCO₃ (1 × 15 mL), H₂O (1 × 15 mL), and brine (1 × 15 mL). The solvent was dried (Na₂SO₄) and removed under reduced pressure. The oily residue was purified by column chromatography on silica gel with petroleum ether / ethyl acetate (1:1) as eluent to obtain **5** (1.13 g, 75 %) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 0.90 (d, ³J = 6.7 Hz, 3H, CH₃CHCH₃), 0.96 (d, ³J = 6.6 Hz, 3H, (CH₃CHCH₃)), 1.37-1.45 (m, 1H, (CH₃)₂CHCH₂), 1.61-1.76 (m, 2H, CHCH₂CH), 2.66 (d, ³J = 2.2 Hz, 3H, CH₃NH), 3.07 (s, 3H, CH₃N), 3.34 (br s, 1H, NNHCH₃), 5.04 (d, ²J = 12.3 Hz, 1H, PhCHHO), 5.08 (d, ²J = 12.3 Hz, 1H, PhCHHO), 5.20 (td, ³J = 10.0 Hz, ³J = 4.1 Hz, 1H, NHCHCO), 5.37 (d, ³J = 9.5 Hz, 1H, NHCHCO), 7.25-7.34 (m, 5H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 21.61 (CH₃CHCH₃), 23.47 (CH₃CHCH₃), 24.82 ((CH₃)₂CHCH₂), 31.88 (CH₃N), 35.62 (CH₃NH), 42.73 (CHCH₂CH), 49.37 (NHCHCO), 66.62 (PhCH₂O), 127.96 (C-2', C-6'), 128.10 (C-4'), 128.43 (C-3', C-4'), 136.55 (C-1'), 156.24 (OCONH), 175.19 (CHCON). C₁₆H₂₅N₃O₃ (307.39 g/mol).

***N*-(Benzyloxycarbonyl)-phenylalanyl-methylazaalanine-nitrile (6)**




Sodium acetate (0.34 g, 4.09 mmol) and cyanogen bromide (0.51 g, 4.83 mmol) were added to a solution of *N*-(benzyloxycarbonyl)-phenylalanine 1,2-dimethylhydrazide (**4**; 0.50 g, 1.46 mmol) in MeOH (20 mL). The mixture was stirred at room temperature for 5 h and the solvent was removed under reduced pressure. The residue was suspended in H₂O (10 mL), a pH of 1-2 was adjusted (10 % KHSO₄), and it was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with H₂O (1 × 10 mL), sat. NaHCO₃ (2 × 10 mL), and brine (1 × 10 mL). The solvent was dried (Na₂SO₄) and removed in vacuo. The oily residue (0.48 g) was purified by column chromatography on silica gel using petroleum ether / ethyl acetate (2:1) as eluent. The obtained oil crystallized at room temperature after a few days. The crystals were separated and washed with petroleum ether and dried in a desiccator to obtain **6** (0.22 g, 41 %): mp 77-81 °C; [α]_D²⁰ = +15.8 (c = 1.35, MeOH); ¹H NMR (500 MHz, CDCl₃) mixture of *cis/trans* rotamers (only the data of the major rotamer are disclosed) δ 2.88 (dd, ²*J* = 14.0 Hz, ³*J* = 8.4 Hz, 1H, PhCHHCH), 3.11 (dd, ²*J* = 14.2 Hz, ³*J* = 5.4 Hz, 1H, PhCHHCH), 3.19 (s, 3H), 3.23 (s, 3H) (2×CH₃N), 4.98 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.04 (d, ²*J* = 12.0 Hz, 1H, PhCHHO), 5.04- 5.10 (m, 1H, NHCHCO), 5.30 (d, ³*J* = 8.2 Hz, 1H, NHCHCO), 7.12-7.40 (m, 10H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) mixture of *cis/trans* rotamers, w = weak (refers to minor rotamer), i = intensive (refers to major rotamer) δ 29.99 (w), 30.43 (i), 38.37 (i), 39.63 (w), 40.61 (w), 41.19 (i) (CH₃NCN, PhCH₂CH, CH₃NCO), 51.74 (w), 51.96 (i) (NHCHCO), 67.02 (i), 67.16 (w) (PhCH₂O), 113.23 (w), 113.36 (i), (NCN), 127.34 (C-4'), 127.95 (C-2'', C-6''), 128.19 (C-4''), 128.51, 128.78, 129.20 (C-2', C-6', C-3', C-5', C-3'', C-5''), 135.32, 135.96 (C-1', C-1''), 155.98 (OCONH), 173.29 (i), 173.35 (w) (CHCONN); MS (ESI) *m/z* (rel. intensity) (pos.) 389 (47, [M + Na]⁺), 384 (26, [M + NH₄]⁺), 367 (100, [M + H]⁺), 323 (42, [M - CO₂ + H]⁺), (neg.) 365 (26, [M - H]⁻), 230 (47, [M - BnOH - HCN - H]⁻), 201 (100, [M - BnOH - CH₃NHCN - H]⁻); FTIR (KBr, cm⁻¹) 3392 (N-H), 2225 (C≡N), 1721 (C=O, OCONH), 1685 (C=O, CON), 1528 (C=C_{arom}), 1250 (C-N, OCONH). Anal. C₂₀H₂₂N₄O₃ (366.41 g/mol) calcd C 65.56, H 6.05, N 15.29; found C 65.72, H 6.14, N 15.12.

N-(Benzyloxycarbonyl)-leucyl-methylazaalanine-nitrile (**7**)




Sodium acetate (0.43 g, 5.21 mmol) and cyanogen bromide (0.22 g, 2.05 mmol) were added to a solution of *N*-(benzyloxycarbonyl)-leucine 1,2-dimethylhydrazide (**5**; 0.57 g, 1.86 mmol) in MeOH (20 mL). The mixture was stirred at room temperature for 2 h, additional cyanogen bromide (0.22 g, 2.05 mmol) was added and stirring was continued for 2 h. The solvent was evaporated and the residue was suspended in H₂O (10 mL). A pH of 1-2 was adjusted (10 % KHSO₄), it was extracted with ethyl acetate (1 × 40 mL, 3 × 30 mL), and the combined organic layers were washed with H₂O (1 × 10 mL), sat. NaHCO₃ (2 × 10 mL), and brine (1 × 10 mL). The solvent was dried (Na₂SO₄) and removed under reduced pressure. The oily crude product (0.70 g) was purified on silica gel with petroleum ether / ethyl acetate (2:1) as eluent to obtain **7** (0.46 g, 74 %) as colorless oil: $[\alpha]_{\text{D}}^{20} = +2.96$ (*c* = 1.01, MeOH); ¹H NMR (500 MHz, CDCl₃) δ 0.95 (d, ³*J* = 6.6 Hz, 3H, CH₃CHCH₃), 1.01 (d, ³*J* = 6.3 Hz, 3H, CH₃CHCH₃), 1.47-1.53 (m, 2H, CHCH₂CH), 1.68-1.80 (m, 1H, CH₃CHCH₃), 3.18 (s, 3H), 3.23 (s, 3H) (2 × CH₃N), 4.83 (td, ³*J* = 10.0 Hz, ³*J* = 5.0 Hz, 1H, NHCHCO), 5.03 (d, ²*J* = 12.0 Hz, 1H, PhCHHO), 5.09 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.20 (d, ³*J* = 8.9 Hz, NHCHCO), 7.27-7.36 (m, 5H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 21.31 (CH₃CHCH₃), 23.22 (CH₃CHCH₃), 24.79 ((CH₃)₂CHCH₂), 30.44 (NCH₃), 40.99 (NCH₃), 41.52 (CHCH₂CH), 49.59 (NHCHCO), 67.04 (PhCH₂O), 49.59 (NHCHCO), 113.45 (NCN), 127.95 (C-2', C-6'), 128.20 (C-4'), 128.53 (C-3', C-4'), 136.02 (C-1'), 156.40 (OCONH), 174.63 (CHCON); MS (ESI) *m/z* (rel. intensity) (pos.) 350 (29, [M + NH₄]⁺), 333 (100, [M + H]⁺), 289 (13, [M - CO₂ + H]⁺), (neg.) 391 (26, [M + CH₃COO]⁻), 331 (100, [M - H]⁻), 223 (4, [M - BnOH - H]⁻). Anal. C₁₇H₂₄N₄O₃ (332.40 g/mol) calcd C 61.43, H 7.28, N 16.86; found C 60.38, H 7.46, N 15.77.

***N*-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-benzylidenehydrazide**




N-(Benzyloxycarbonyl)-phenylalanine 1-methylhydrazide (**3**; 0.5 g, 1.53 mmol) was dissolved in THF (10 mL), and benzaldehyde (0.15 mL, 1.53 mmol) was added. After stirring at room temperature for 4 h, one more equivalent (0.15 mL, 1.53 mmol) of benzaldehyde was added and stirring was continued for 1 h. The mixture was evaporated to dryness and the crude product was recrystallized from petroleum ether / ethyl acetate to yield a colorless solid (0.34 g, 53 %): mp 128-130 °C; ¹H NMR (500 MHz, CDCl₃) δ 3.03 (dd, ²*J* = 13.9 Hz, ³*J* = 6.9 Hz, 1H, PhCHHCH), 3.17 (dd, ²*J* = 13.7 Hz, ³*J* = 5.5 Hz, 1H, PhCHHCH), 3.34 (s, 3H, CH₃N), 5.04 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.09 (d, ²*J* = 11.9 Hz, PhCHHO), 5.61 (d, ³*J* = 8.6 Hz, 1H, NHCHCO), 5.76-5.83 (m, 1H, NHCHCO), 7.07-7.11 (m, 2H, H_{arom}), 7.12-7.20 (m, 3H, H_{arom}), 7.26-7.36 (m, 5H, H_{arom}), 7.38-7.45 (m, 3H, H_{arom}), 7.66 (s, 1H, N=CHPh); 7.67-7.71 (m, 2H, H_{arom}); ¹³C NMR δ 28.13, 39.22 (CH₃N, PhCH₂CH), 52.98 (NHCHCO), 66.68 (PhCH₂O), 126.72, 127.34, 127.97, 128.24, 128.45, 128.80, 129.35, 130.07, 134.15, 136.52, 136.56 (C_{arom}), 149.21 (N=CHPh), 155.69 (OCONH), 172.73 10 (CHCON). One aromatic carbon signal could not be identified. Anal. C₂₅H₂₅N₃O₃ (415.48 g/mol) calcd C 72.27, H 6.06, N 10.11; found C 72.16, H 6.14, N 9.57.

***N*-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-benzylhydrazide**




N-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-benzylidenehydrazide (0.5 g, 1.2 mmol) was dissolved in CH₂Cl₂ (5 mL). At 0 °C, a solution of *p*-toluenesulfonic acid (1.37 g, 7.2 mmol) in CH₂Cl₂ / MeOH (3:1; 10 mL) and dimethylamine borane (DMAB; 0.11 g, 1.92 mmol) were added. The mixture was allowed to react at room temperature for 1.5 h before additional 1.6 equivalents DMAB (0.11 g, 1.92 mol) were added. After 2 h, 1.5 M NaOH (10 mL) was added and stirring was continued for 30 min. The volume was reduced in vacuo, and the aqueous residue was extracted with CH₂Cl₂ (3 × 15 mL). The combined organic layers were washed with H₂O (1 × 15 mL) and brine (1 × 15 mL) and the solvent was dried (Na₂SO₄). It was evaporated and the residue was purified on silica gel using petroleum ether / ethyl acetate (2:1) as mobile phase to obtain a colorless oil (0.42 g, 84 %): ¹H NMR (500 MHz, CDCl₃) δ 2.91 (dd, ³*J* = 7.3 Hz, ⁵*J* = 2.2 Hz, 2H, PhCH₂CH), 3.08 (s, 3H, CH₃N), 3.30 (s, 1H, NHCH₂), 3.74 (dd, ²*J* = 11.8 Hz, ³*J* = 5.5 Hz, 1H, PhCHHNH), 3.87 (dd, ²*J* = 11.5 Hz, ³*J* = 6.8 Hz, 1H, PhCHHNH), 5.02 (d, ²*J* = 12.7 Hz, 1H, PhCHHO), 5.06 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.45 (³*J* = 9.2 Hz, 1H, NHCHCO), 5.49-5.56 (m, 1H, NHCHCO), 7.10-7.38 (m, 15H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 32.96 (CH₃N), 39.97 (PhCH₂CH), 51.56 (NHCHCO), 52.95 (PhCH₂NH), 66.55 (PhCH₂O), 126.67, 127.91, 127.94, 128.21, 128.42, 128.63, 128.86, 129.03, 129.44, 135.91, 136.53, 136.83 (C_{arom}), 155.62 (OCONH), 173.92 (CHCON). C₂₅H₂₇N₃O₃ (417.21 g/mol).

***N*-(Benzyloxycarbonyl)-phenylalanyl-methylazaphenylalanine-nitrile (**8**)**




Sodium acetate (0.22 g, 2.69 mmol) and cyanogen bromide (0.15 g, 1.44 mmol) were added to a solution of *N*-(benzyloxycarbonyl)-phenylalanine 1-methyl-2-benzylhydrazide (0.40 g, 0.96 mmol) in MeOH (10 mL). The mixture was stirred at room temperature for 24 h, three additional equivalents of cyanogen bromide (0.30 g, 2.88 mmol) were added and stirring was continued for 3 h. The solvent was removed under reduce pressure, and the oily residue was suspended in H₂O (5 mL). A pH of 1-2 was adjusted (10 % KHSO₄), it was extracted with ethyl acetate (5 × 15 mL), and the combined organic layers were washed with H₂O (1 × 15 mL), sat. NaHCO₃ (1 × 15 mL) and brine (1 × 15 mL). The solvent was dried (Na₂SO₄) and evaporated. The oily crude product (0.40 g) was purified on silica gel with petroleum ether / ethyl acetate (2:1) as the mobile phase to obtain **8** (0.25 g, 60 %) as a colorless oil: $[\alpha]_D^{20} = +47.1$ (c = 1.03, MeOH); ¹H NMR (500 MHz, CDCl₃) δ 2.81-3.00 (m, 2H, PhCH₂CH), 3.10 (s, 3H, CH₃N), 4.46-4.56 (m, 2H, PhCH₂N), 5.03 (d, ²J = 12.7 Hz, 1H, PhCHHO), 5.06 (d, ²J = 12.6 Hz, 1H, PhCHHO), 5.13-5.17 (m, 1H, NHCHCO), 5.30 (d, ³J = 8.5 Hz, 1H, NHCHCO), 7.11-7.45 (m, 15H, H_{arom}); ¹³C (125 MHz, CDCl₃) δ 32.28 (CH₃NCO), 38.40 (PhCH₂CH), 52.42 (NHCHCO), 59.06 (PhCH₂NCN), 67.01 (PhCH₂O), 112.24 (NCN), 127.27, 127.99, 128.19, 128.51, 128.73, 129.19, 129.31, 129.83, 130.21, 131.33, 135.37, 136.05 (C_{arom}), 155.97 (OCONH), 173.48 (CHCON); MS (EI) *m/z* (rel. intensity) 442 (5, *M*⁺), 307 (3, [*M* - Bn - CO₂]⁺), 282 (5, [*M* - N(CH₃)N(CH₂Ph)CN]⁺), 91 (100, C₇H₇⁺). Anal. C₂₆H₂₆N₄O₃ (442.52 g/mol) calcd C 70.57, H 5.92, N 12.66; found C 70.81, H 6.49, N 11.69.

***N*-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-phenylethylidenehydrazide**




N-(Benzyloxycarbonyl)-phenylalanine 1-methylhydrazide (**3**; 0.5 g, 1.53 mmol) was dissolved in THF (10 mL), and phenylacetaldehyde (0.17 mL, 1.53 mmol) was added. After stirring at room temperature for 4 h, one more equivalent (0.17 mL, 1.53 mmol) of phenylacetaldehyde was added and stirring was continued for 1 h. The mixture was evaporated to dryness and the residue was suspended in petroleum ether (5 mL). The product was isolated by suction filtration, washed with petroleum ether and dried in a desiccator to yield a colorless solid (0.55 g, 84 %): mp 103-104 °C; ¹H NMR (500 MHz, CDCl₃) δ 2.91 (dd, ²*J* = 13.6 Hz, ³*J* = 7.3 Hz, 1H, PhCHHCH), 3.10 (dd, ²*J* = 13.7 Hz, ³*J* = 5.2 Hz, 1H, PhCHHCH), 3.15 (s, 3H, CH₃N), 3.63 (d, ³*J* = 5.4 Hz, 2H, PhCH₂CH=N), 5.03 (d, ²*J* = 12.6 Hz, 1H, PhCHHO), 5.07 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.54 (d, ³*J* = 8.8 Hz, 1H, NHCHCO), 5.60-5.67 (m, 1H, NHCHCO), 7.06-7.10 (m, 2H, H_{arom}), 7.15-7.36 (m, 14H, H_{arom}, CH₂CH=N); ¹³C NMR (125 MHz, CDCl₃) δ 27.86 (NCH₃), 39.15 (PhCH₂CH), 39.47 (PhCH₂C=N), 52.94 (NHCHCO), 66.62 (PhCH₂O), 126.67, 126.96, 127.95, 128.23, 128.43, 128.85, 128.97, 129.37, 136.45, 136.56, 136.73 (C_{arom}), 142.09 (CH=N), 155.68 (OCONH), 172.48 (CHCON). One aromatic carbon signal could not be identified. Anal. C₂₆H₂₇N₃O₃ (429.21 g/mol) calcd C 72.71, H 6.34, N 9.78; found C 72.83, H 6.42, N 9.26.

***N*-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-phenylethylhydrazide**




N-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-phenylethylidenehydrazide (0.59 g, 1.37 mmol) was dissolved in CH₂Cl₂ (5 mL). At 0 °C, a solution of *p*-toluenesulfonic acid (1.56 g, 8.22 mmol) in CH₂Cl₂ / MeOH (3:1; 10 mL) and dimethylamine borane (DMAB; 0.13 g, 2.19 mmol) were added. The mixture was allowed to react at room temperature for 1.5 h. 1.5 M NaOH (10 mL) was added and stirring was continued for 30 min. The organic solvents were evaporated and the aqueous residue was extracted with CH₂Cl₂ (3 × 15 mL). The combined organic layers were washed with H₂O (1 × 15 mL) and brine (1 × 15 mL) and dried (Na₂SO₄). The solvent was removed in vacuo to obtain a colorless oil (0.39 g, 66 %): ¹H NMR (500 MHz, CDCl₃) δ 2.70 (dd, ²*J* = 13.7 Hz, ³*J* = 7.4 Hz, 1H, PhCH₂CH), 2.80 (br s, 1H, NNHCH₂), 2.85 (dd, ²*J* = 12.9 Hz, ³*J* = 6.1 Hz, 1H, PhCH₂CH), 2.89-2.94 (m, 2H, PhCH₂CH₂), 2.94 (s, 3H, NCH₃), 2.96-3.07 (m, 2H, CH₂CH₂N), 5.02 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.07 (d, ²*J* = 12.0 Hz, 1H, PhCHHO), 5.41-5.52 (m, 2H, NHCHCO, NHCHCO), 7.00-7.40 (m, 15H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 32.58 (NCH₃), 33.95 (NCH₂CH₂), 39.73 (PhCH₂CH), 49.22 (CH₂CH₂Ph), 51.56 (NHCHCO), 66.59 (PhCH₂O), 126.55, 126.67, 127.92, 127.98, 128.21, 128.44, 128.58, 128.65, 129.43, 136.52, 136.81, 138.55 (C_{arom}), 155.67 (OCONH), 173.85 (CHCONH). C₂₆H₂₉N₃O₃ (431.53 g/mol).

***N*-(Benzyloxycarbonyl)-phenylalanyl-methylazahomophenylalanine-nitrile (9)**




Sodium acetate (0.21 g, 2.52 mmol) and cyanogen bromide (0.14 g, 1.35 mmol) were added to a solution of *N*-(benzyloxycarbonyl)-phenylalanine 1-methyl-2-phenylethylhydrazide (0.39 g, 0.90 mmol) in MeOH (10 mL). The mixture was stirred at room temperature for 4 h, three additional equivalents of cyanogen bromide (0.29 g, 2.70 mmol) were added and stirring was continued for 24 h. The solvent was removed in vacuo, and the oily residue was suspended in H₂O (5 mL). A pH of 1-2 was adjusted (10 % KHSO₄), it was extracted with ethyl acetate (1 × 40; 3 × 10 mL), and the combined organic layers were washed with H₂O (1 × 10 mL), sat. NaHCO₃ (2 × 10 mL), H₂O (1 × 10 mL), and brine (1 × 10 mL). The solvent was dried (Na₂SO₄) and evaporated. The oily residue was purified by column chromatography on silica gel with petroleum ether / ethyl acetate (2:1) as eluent to obtain **8** (0.23 g, 56 %) as a colorless oil: $[\alpha]_D^{20} = +23.6$ (c = 1.04, MeOH); ¹H NMR (500 MHz, CDCl₃) δ 2.73 (dd, ²J = 14.1 Hz, ³J = 8.4 Hz, 1H, PhCHHCH), 2.95 (dd, ²J = 14.2 Hz, ³J = 5.4 Hz, 1H, PhCHHCH), 2.98-3.13 (m, 2H, PhCH₂CH₂), 3.15 (s, 3H, NCH₃), 3.68 (t, ³J = 7.3 Hz, 2H, NCH₂CH₂), 4.72-4.80 (m, 1H, NHCHCO), 4.99 (d, ²J = 12.3 Hz, 2H, PhCHHO), 5.06 (d, ²J = 12.3 Hz, 1H, PhCHHO), 5.14 (d, ³J = 8.5 Hz, 1H, NHCHCO), 6.98 (dd, ³J = 7.3 Hz, ⁴J = 1.6 Hz, 2H, H_{arom}), 7.20-7.40 (m, 13H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 31.48 (NCH₃), 32.79 (NCH₂CH₂), 38.02 (PhCH₂CH), 51.84 (CH₂CH₂Ph), 54.92 (NHCHCO), 66.96 (PhCH₂O), 112.17 (NCN), 127.25, 127.98, 128.18, 128.50, 128.74, 128.86, 128.96, 129.15, 129.44, 135.13, 136.07, 136.08 (C_{arom}), 155.88 (OCONH), 173.44 (CHCONH); MS (EI) *m/z* (rel. intensity) 456 (21, *M*⁺), 321 (14, [*M* – Bn – CO₂]⁺), 282 (40, [*M* – N(CH₃)N(CH₂CH₂Ph)CN]⁺), 91 (100, C₇H₇⁺). Anal. C₂₇H₂₈N₄O₃ (456.54 g/mol) calcd C 71.03, H 6.18, N 12.27; found C 71.12, H 6.53, N 11.50.

***N*-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-pentylidenehydrazide**




N-(Benzyloxycarbonyl)-phenylalanine 1-methylhydrazide (**3**; 0.5 g, 1.53 mmol) was dissolved in THF (10 mL), and valeraldehyde (0.16 mL, 1.53 mmol) was added. After stirring at room temperature for 4 h, one more equivalent (0.16 mL, 1.53 mmol) of valeraldehyde was added and stirring was continued for 2 h. The mixture was evaporated to dryness to obtain a semisolid product (0.59 g, 98 %): ^1H NMR (500 MHz, CDCl_3) δ 0.93 (t, $^3J = 7.4$ Hz, 3H, CH_3CH_2), 1.33-1.42 (m, 2H, CH_3CH_2), 1.49-1.58 (m, 2H, $\text{CH}_3\text{CH}_2\text{CH}_2$), 2.27-2.34 (m, 2H, $\text{CH}_2\text{CH}_2\text{CH}$), 2.89 (dd, $^2J = 13.9$ Hz, $^3J = 7.1$ Hz, 1H, PhCHHCH), 3.11 (dd, $^2J = 13.9$ Hz, $^3J = 5.1$ Hz, 1H, PhCHHCH), 3.16 (s, 3H, NCH_3), 5.01 (d, $^2J = 12.6$ Hz, 1H, PhCHHO), 5.05 (d, $^2J = 12.3$ Hz, 1H, PhCHHO), 5.55 (d, $^3J = 9.2$ Hz, 1H, NHCHCO), 5.58-5.64 (m, 1H, NHCHCO), 7.02 (t, $^3J = 5.2$ Hz, 1H, $\text{CH}_2\text{CH}=\text{N}$), 7.07-7.12 (m, 2H, H-2', H-6'), 7.14-7.25 (m, 3H, H-3', H-4', H-5'), 7.25-7.37 (m, 5H, H-2'', H-6'', H-3'', H-5'', H-4''); ^{13}C NMR (125 MHz, CDCl_3): δ 13.86 (CH_3CH_2), 22.29 (CH_3CH_2), 27.70 ($\text{CH}_3\text{CH}_2\text{CH}_2$), 28.65 ($\text{CH}_2\text{CH}_2\text{CH}$), 32.54 (CH_3N), 39.04 (PhCH_2CH), 52.91 (NHCHCO), 66.57 (PhCH_2O), 126.61, 127.93, 128.17, 128.37, 128.41, 129.37, 136.59, 136.81 (C_{arom}), 143.94 ($\text{CH}_2\text{CH}=\text{N}$), 155.68 (OCONH), 172.35 (CHCON). $\text{C}_{23}\text{H}_{29}\text{N}_3\text{O}_3$ (395.49 g/mol).

***N*-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-pentylhydrazide**




N-(Benzyloxycarbonyl)-phenylalanine 1-methyl-2-pentylidenehydrazide (0.58 g, 1.47 mmol) was dissolved in CH₂Cl₂ (5 mL). At 0 °C, a solution of *p*-toluenesulfonic acid (1.37 g, 7.2 mmol) in CH₂Cl₂ / MeOH (3:1; 10 mL) and dimethylamine borane (DMAB; 0.14 g, 2.36 mmol) were added. After stirring at room temperature for 1.5 h, one more of dimethylamine borane (0.14 mg, 2.36 mmol) was added. After stirring for 2 h, 1.5 M NaOH (10 mL) was added and stirring was continued for 30 min. The organic solvents were evaporated and the aqueous residue was extracted with CH₂Cl₂ (3 × 15 mL). The combined organic layers were washed with H₂O (1 × 15 mL) and brine (1 × 15 mL) and dried (Na₂SO₄). The solvent was removed in vacuo to obtain a colorless oil (0.55 g, 95 %): ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, ³*J* = 6.6 Hz, 3H, CH₃CH₂), 1.22-1.31 (m, 2H, CH₃CH₂), 1.32-1.42 (m, 2H, CH₃CH₂CH₂), 2.50-2.61 (m, 2H, CH₂CH₂NH), 2.68-2.75 (m, 1H, PhCHHCH), 2.76-2.81 (m, 1H, PhCHHCH), 2.88-3.00 (m, 2H, NHCH₂), 3.00 (s, 3H, NHCH₃), 5.01 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.06 (d, ²*J* = 12.3 Hz, 1H, PhCHHO), 5.41-5.54 (m, 2H, NHCHCO, NHCHCO), 7.09-7.36 (m, 10H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 13.93 (CH₃CH₂), 22.52 (CH₃CH₂), 27.24 (CH₃CH₂CH₂), 29.23 (CH₂CH₂NH), 32.54 (CH₃N), 39.76 (PhCH₂CH), 48.35 (CH₂NH), 51.61 (NHCHCO), 66.53 (PhCH₂O), 126.64, 127.12, 127.89, 128.17, 128.41, 129.46, 136.55, 136.94 (C_{arom}), 155.63 (OCONH), 173.81 (CHCON). C₂₃H₃₁N₃O₃ (397.51 g/mol).

***N*-(Benzyloxycarbonyl)-phenylalanyl-methylazahomonorleucine-nitril (10)**




Sodium acetate (0.23 g, 2.83 mmol) and cyanogen bromide (0.16 g, 1.51 mmol) were added to a solution of *N*-(benzyloxycarbonyl)-phenylalanine 1-methyl-2-pentylhydrazide (0.40 g, 1.01 mmol) in MeOH (10 mL). After stirring at room temperature for 4 h, additional three equivalents of cyanogen bromide (0.29 g, 2.70 mmol) were added and stirring was continued for 20 h. The solvent was removed in vacuo, and the oily residue was suspended in H₂O (5 mL). A pH of 1-2 was adjusted (10 % KHSO₄), it was extracted with ethyl acetate (1 × 40; 3 × 10 mL), and the combined organic layers were washed with H₂O (1 × 10 mL), sat. NaHCO₃ (2 × 10 mL), H₂O (1 × 10 mL), and brine (1 × 10 mL). The solvent was dried (Na₂SO₄) and evaporated. The crude product (0.53 g) was purified by column chromatography on silica gel with petroleum ether / ethyl acetate (2:1) as eluent to obtain **10** (0.28 g, 65 %) as a colorless oil: $[\alpha]_D^{20} = +21.2$ (c = 1.08, MeOH); ¹H NMR (500 MHz, CDCl₃) δ 0.91 (t, ³J = 6.9 Hz, 3H, CH₃CH₂), 1.33-1.45 (m, 4H, CH₃CH₂CH₂), 1.70-1.79 (m, 2H, CH₂CH₂N), 2.85 (dd, ²J = 13.9 Hz, ³J = 8.5 Hz, 1H, PhCHHCH), 3.13 (dd, ²J = 14.4 Hz, ³J = 4.9 Hz, 1H, PhCHHCH), 3.20 (s, 3H, NCH₃), 3.22-3.32 (m, 1H, CH₂CHHN), 3.40-3.48 (m, 1H, CH₂CHHN), 4.98 (d, ²J = 12.3 Hz, 1H, PhCHHO), 5.03 (dd, ²J = 12.0 Hz, 1H, PhCHHO), 5.01-5.07 (m, 1H, NHCHCO), 5.29-5.34 (d, ³J = 8.9 Hz, 1H, NHCHCO), 7.15-7.20 (m, 2H, H-2', H-6'), 7.21-7.35 (m, 8H, H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 13.79 (CH₃CH₂), 22.26 (CH₃CH₂), 26.26 (CH₃CH₂CH₂), 28.54 (CH₂CH₂N), 31.45 (CH₃N), 38.29 (PhCH₂CH), 52.22 (NHCHCO), 54.05 (CH₂CH₂N), 66.92 (PhCH₂O), 112.39 (NCN), 127.45, 127.92, 128.13, 128.47, 128.72, 129.19 (C_{arom}), 135.49, 136.03 (C-1', C-1''), 155.87 (OCONH), 173.39 (CHCON); MS (EI) *m/z* (rel. intensity) 422 (21, M^{•+}), 287 (4, [M - Bn - CO₂]⁺), 282 (21, [M - N(CH₃)N(CH₂CH₂CH₂CH₂CH₃)CN]⁺), 91 (100, C₇H₇⁺). Anal. C₂₄H₃₀N₄O₃ (422.52 g/mol) calcd C 68.22, H 7.16, N 13.26; found C 67.80, H 7.16, N 13.16.

N-(*tert*-Butoxycarbonyl)-alanine-amide




N-(*tert*-Butoxycarbonyl)-alanine (1.0 g, 5.29 mmol) was dissolved in THF (10 mL) and cooled to $-25\text{ }^{\circ}\text{C}$. To the stirred solution, *N*-methylmorpholine (0.59 mL, 5.29 mmol) and isobutylchloroformate (0.69 mL, 5.29 mmol) were added consecutively followed by 25 % NH_3 (1.8 mL, 26.45 mmol). The resulting mixture was stirred at room temperature for 2 h and evaporated. H_2O (10 mL) was added, a pH of 1-2 was adjusted (10 % KHSO_4), and the aqueous mixture was extracted with ethyl acetate ($4 \times 15\text{ mL}$). The combined organic layers were washed with H_2O ($1 \times 15\text{ mL}$), sat. NaHCO_3 ($2 \times 15\text{ mL}$), and brine ($1 \times 15\text{ mL}$). The solvent was dried (Na_2SO_4) and evaporated to obtain a colorless solid (0.82 g, 82 %): mp $124\text{--}125\text{ }^{\circ}\text{C}$ (lit.^[7] mp $124\text{--}125\text{ }^{\circ}\text{C}$); ^1H NMR (500 MHz, CDCl_3) δ 1.35 (d, $^3J = 7.3\text{ Hz}$, 3H, CHCH_3), 1.42 (s, 9H, $\text{C}(\text{CH}_3)_3$), 4.18 (br s, 1H, NHCHCO), 5.04 (br s, 1H, CONHCH), 5.62 (s, 1H, CONHH), 6.22 (s, 1H, CONHH); ^{13}C NMR (125 MHz, CDCl_3) δ 18.19 (CHCH_3), 28.30 ($\text{C}(\text{CH}_3)_3$), 49.61 (NHCHCO), 80.23 ($\text{C}(\text{CH}_3)_3$), 155.54 (OCONH), 175.16 (CHCONH_2). Anal. $\text{C}_8\text{H}_{16}\text{N}_2\text{O}_3$ (188.23 g/mol) calcd C 51.05, H 8.57, N 14.88; found C 50.67, H 8.93, N 14.42.

Alanine-amide hydrochloride




Under ice-cooling, acetyl chloride (10.95 ml, 154.13 mmol) was added dropwise to EtOH (10 ml). To the stirred mixture, a solution of *N*-(*tert*-Butoxycarbonyl)-alanine-amide (0.69 g, 3.66 mmol) in ethyl acetate (10 ml) was added. After 1 h, the formed precipitate was separated by suction filtration, washed with ethyl acetate (5 mL) and dried in a desiccator to obtain a colorless solid (0.40 g, 87 %): mp 215-217 °C (lit.^[8] mp 196-199 °C); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.36 (d, ³*J* = 7.3 Hz, 3H, CH₃), 3.75 (q, ³*J* = 7.0 Hz, 1H, CHCO), 7.41 (s, 1H, CONHH), 7.92 (s, 1H, CONHH), 8.25 (s, 3H, NH₃⁺); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 17.18 (CH₃), 48.22 (CHCO), 171.42 (CO) Anal. C₃H₈N₂O × HCl (124.57 g/mol) calcd C 28.93, H 7.28, N 22.49; found C 28.65, H 7.57, N 21.87.

***N*-(Benzyloxycarbonyl)-phenylalanyl-alanine-amide**




N-(Benzyloxycarbonyl)-phenylalanine (0.87 g, 2.92 mmol) was dissolved in THF (10 mL) and cooled to $-25\text{ }^{\circ}\text{C}$. To the stirred solution, *N*-methylmorpholine (0.33 ml, 2.92 mmol) and isobutylchloroformate (0.38 ml, 2.92 mmol) were added consecutively. 1 M NaOH (3.2 mL) was added to alanine-amide hydrochloride (0.36 g, 2.92 mmol) dissolved H_2O (5 mL), and the resulting solution was added to the reaction mixture, which was stirred at room temperature for 2 h. The organic solvent was evaporated and the residue was suspended in H_2O (5 mL), separated by suction filtration, washed with 10 % KHSO_4 . (15 mL), sat. NaHCO_3 (15 mL) and H_2O (3×15 mL) and dried in a desiccator to obtain a colorless solid (0.83 g, 77 %): mp $223\text{--}224\text{ }^{\circ}\text{C}$ (lit.^[9] mp $212\text{--}214\text{ }^{\circ}\text{C}$); ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 1.22 (d, $^3J = 7.0$ Hz, 3H, CH_3), 2.73 (dd, $^2J = 10.9$ Hz, $^3J = 2.8$ Hz, 1H, PhCHHCH), 3.03 (dd, $^2J = 13.8$ Hz, $^3J = 3.8$ Hz, 1H, PhCHHCH), 4.24–4.28 (m, 2H, NHCHCONH_2 , NHCHCONH), 4.94 (s, 2H, PhCH_2O), 6.98 (s, 1H, NHCHCONH), 7.17–7.48 (m, 11H, NHCHCONH_2 , 10H, H_{arom}), 7.47 (d, 1H, $^2J = 8.5$ Hz, CONHH), 8.00 (d, 1H, $^2J = 7.3$ Hz, CONHH); ^{13}C NMR (125 MHz, CDCl_3) δ 18.61 (CH_3), 37.49 (PhCH_2CH), 48.14 (NHCHCONH_2), 56.26 (NHCHCONH), 65.34 (PhCH_2O), 126.35 (C-4'), 127.50 (C-2'', C-6''), 127.77 (C-4''), 128.16, 128.41, 129.32 (C-2', C-6', C-3', C-5', C-3'', C-5''), 137.16, 138.25 (C-1', C-1''), 155.98 (OCONH), 171.12 (CHCONH), 174.13 (CHCONH_2). Anal. $\text{C}_{20}\text{H}_{23}\text{N}_3\text{O}_4$ (369.42 g/mol) calcd C 65.03, H 6.28, N 11.37; found C 65.02, H 6.31, N 11.01.

***N*-(Benzyloxycarbonyl)-phenylalanyl-alanine-nitrile (12)**




Cyanuric chloride (0.30 g, 1.62 mmol) was added to a solution of *N*-(benzyloxycarbonyl)-phenylalanyl-alanine-amide (0.60 g, 1.62 mmol) in DMF (10 mL). After stirring for 2 h at room temperature, DMF was evaporated. Ice-cold sat. NaHCO₃ (10 mL) was added and the mixture was extracted with ethyl acetate (4 × 15 mL). The combined organic layers were washed with H₂O (3 × 15 mL) and brine (1 × 15 mL), dried (Na₂SO₄), and the solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel with petroleum ether / ethyl acetate (1:1) as eluent to obtain **12** (0.45 g, 79 %) as a colorless solid: mp 143-145 °C; [α]_D²⁰ = -28.5 (c = 1.00, MeOH); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.42 (d, ³*J* = 7.3 Hz, 3H, CH₃), 2.78 (dd, ²*J* = 10.3 Hz, ³*J* = 3.5 Hz, 1H, PhCHHCH), 2.96 (dd, ³*J* = 13.6 Hz, ²*J* = 4.8 Hz, 1H, PhCHHCH), 4.20-4.25 (m, 1H, NHCHCO), 4.75 (quint, ³*J* = 7.2 Hz, 1H, NHCHCN), 4.92 (d, ²*J* = 12.9 Hz, 1H, PhCHHO); 4.96 (d, ²*J* = 12.6 Hz, 1H, PhCHHO), 7.18-7.34 (m, 12H, NHCHCN, NHCHCO, 10H_{arom}); ¹³C NMR (125 MHz, CDCl₃) δ 18.26 (CH₃), 35.73 (PhCH₂CH), 37.39 (NHCHCN), 56.01 (NHCHCO), 65.42 (PHCH₂O), 120.19 (CHCN), 126.49 (C-4'), 127.58 (C-2'', C-6''), 127.82 (C-4''), 128.22, 128.41, 129.31 (C-2', C-6', C-3', C-5', C-3'', C-5''), 137.09, 137.78 (C-1', C-1''), 155.96 (OCONH), 171.52 (CHCONH). MS (ESI) *m/z* (rel. intensity) (pos.) 374 (10, [M + Na]⁺), 369 (100, [M + NH₄]⁺), 352 (93, [M + H]⁺), (neg.) 350 (7, [M - H]⁻), 242 (100, [M - BnOH - H]⁻), 215 (26, M - BnOH - HCN - H]⁻). Anal. C₂₀H₂₁N₃O₃ (351.40 g/mol) calcd C 68.36, H 6.02, N 11.96; found C 68.25, H 5.91, N 11.66.

***N*-(*tert*-Butoxycarbonyl)-methylalanine-amide**




N-(*tert*-Butoxycarbonyl)-methylalanine (1.0 g, 4.92 mmol) was dissolved in THF (10 mL) and cooled to -25 °C. To the stirred solution, *N*-methylnmorpholine (0.54 mL, 4.92 mmol) and isobutylchloroformate (0.64 mL, 4.92 mmol) were added consecutively, followed by 25 % NH_3 (1.68 mL, 24.6 mmol). The resulting mixture was stirred at room temperature for 2 h and the organic solvent was removed under reduced pressure. The formed precipitate was suspended in H_2O (10 mL), a pH of 1-2 was adjusted (10 % KHSO_4), and the aqueous mixture was extracted with ethyl acetate (4×15 mL). The combined organic layers were washed with H_2O (1×15 mL), sat. NaHCO_3 (2×15 mL), and brine (1×15 mL). The solvent was dried (Na_2SO_4) and evaporated to obtain a colorless solid (0.92 g, 92 %): mp 66-68 °C; ^1H NMR (500 MHz, CDCl_3) δ 1.31 (d, $^3J = 7.0$ Hz, 3H, CHCH_3), 1.44 (s, 9H, $\text{C}(\text{CH}_3)_3$), 2.77 (s, 3H, NCH_3), 4.73 (br s, 1H, CHCO), 5.68 (s, 1H, CONHH), 6.08 (s, 1H, CONHH); ^{13}C NMR (125 MHz, CDCl_3) δ 13.50 (CHCH_3), 28.34 ($\text{C}(\text{CH}_3)_3$), 29.84 (NCH_3), 53.20 (CHCO), 80.67 ($\text{C}(\text{CH}_3)_3$), 156.39 (OCONH), 174.16 (CHCONH_2). Anal. $\text{C}_9\text{H}_{18}\text{N}_2\text{O}_3$ (202.26 g/mol) calcd C 53.45, H 8.97, N 13.85; found C 53.15, H 8.74, N 13.36.

Methylalanine-amide hydrochloride




Under ice-cooling, acetyl chloride (10.95 ml, 154.13 mmol) was added dropwise to EtOH (10 ml). To the stirred mixture, a solution of *N*-(*tert*-Butoxycarbonyl)-methylalanine (0.74 g, 3.66 mmol) in ethyl acetate (10 ml) was added. After 1 h, the precipitate was separated by suction filtration, washed with ethyl acetate (5 mL) and dried in a desiccator to obtain a colorless solid (0.37 g, 73 %): mp 192-194 °C (lit.^[10] mp 158 °C); ¹H NMR (500 MHz, DMSO-*d*₆) δ 1.39 (d, ³*J* = 7.3 Hz, 3H, CHCH₃), 2.45 (s, 3H, NCH₃), 3.71 (q, ³*J* = 7.0 Hz, 1H, CHCO), 7.55 (s, 1H CONHH), 7.55 (s, 1H CONHH), 9.18 (s, 2H, NH₂⁺); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 15.74 (CHCH₃), 30.78 (NCH₃), 56.09 (CHCO), 170.52 (CONH₂). Anal. C₄H₁₀N₂O × HCl (138.06 g/mol) calcd C 34.66, H 8.00, N 20.21; found C 34.41, H 7.74, N 19.35.

***N*-(Benzyloxycarbonyl)-phenylalanyl-methylalanine-amide**




N-(Benzyloxycarbonyl)-phenylalanine (0.73 g, 2.44 mmol) was dissolved in THF (10 mL) and cooled to $-25\text{ }^{\circ}\text{C}$. To the stirred solution, *N*-methylmorpholine (0.27 ml, 2.44 mmol) and isobutylchloroformate (0.32 ml, 2.44 mmol) were added consecutively. 1 M NaOH (2.68 mL) was added to methylalanine-amide hydrochloride (0.37 g, 2.68 mmol) dissolved H_2O (5 mL), and the resulting solution was added to the reaction mixture, which was stirred at room temperature for 2 h. The organic solvent was evaporated, the residue was suspended in H_2O (5 mL) and a pH of 1-2 was adjusted (10 % KHSO_4). The aqueous mixture was extracted with ethyl acetate (4 \times 15 mL), the combined organic layers were washed with H_2O (1 \times 15 mL), sat. NaHCO_3 (2 \times 15 mL) and brine (1 \times 15 mL), dried (Na_2SO_4) and evaporated to dryness. The crude product was purified by column chromatography on silica gel with CH_2Cl_2 / MeOH (20:1) as eluent to obtain a colorless solid (0.45 g, 51 %): mp 54-58 $^{\circ}\text{C}$; ^1H NMR (500 MHz, CDCl_3) mixture of *cis/trans* rotamers δ 0.53, 1.23 (d, $^3J = 7.0, 7.0$ Hz, Σ 3H, CHCH_3), 2.679, 2.684 (s, Σ 3H, NCH_3), 2.95-3.08 (m, Σ 2H, PhCH_2CH), 4.42 (q, $^3J = 6.7$ Hz, 1H, CHCONH_2), 4.77-4.81, 4.88-4.93 (m, Σ 1H, NHCHCO), 5.27, 5.45 (s, Σ 2H, PhCH_2O), 5.68 (d, $^2J = 8.2$ Hz, 1H, NHCHCO), 7.16-7.35 (m, Σ 12H, H_{arom} , CONH_2); ^{13}C NMR (125 MHz, CDCl_3) mixture of *cis/trans* rotamers, w = weak (refers to minor rotamer), i = intensive (refers to major rotamer) δ 13.02 (i), 13.07 (w) (CHCH_3), 28.63 (i), 30.82 (w) (NCH_3), 38.92 (w), 39.54 (i) (PhCH_2CH), 51.80 (w), 51.94 (i) (CHCONH_2), 52.46 (w), 55.34 (i) (NHCHCO), 66.99 (w), 67.42 (i) (PhCH_2O), 127.31 (w), 127.50 (i) (C-4'), 127.97 (w), 128.00 (i) (C-2'', C-6''), 128.19 (i), 128.31 (w) (C-4''), 128.52 (w), 128.54 (i) (C-3'', C-5''), 128.74 (w), 128.96 (i) (C-3', C-5'), 129.28 (w), 129.40 (i) (C-2', C-6'), 135.53 (i), 135.73 (w), 136.00 (i), 136.16 (w) (C-1', C-1''), 155.71 (w), 156.79 (i) (OCONH), 171.80 (w), 171.84 (i), 172.26 (w), 172.38 (i) (CONH_2 , CHCONH). Anal. $\text{C}_{21}\text{H}_{25}\text{N}_3\text{O}_4$ (383.45 g/mol) calcd C 65.78, H 6.57, N 10.96; found C 65.72, H 6.71, N 10.54.

***N*-(Benzyloxycarbonyl)-phenylalanyl-sarcosine-nitrile (13)**



Z-Phe-OH (0.72 g, 2.40 mmol) was dissolved in THF (10 mL) and the solution was cooled to $-25\text{ }^{\circ}\text{C}$. *N*-Methylmorpholine (0.27 mL, 2.40 mmol) and isobutylchloroformate (0.31 mL, 2.44 mol) were added consecutively. 1 M NaOH (2.64 mL) was added to *N*-methylaminoacetonitrile hydrochloride (0.28 g, 2.64 mmol) dissolved in H_2O (5 mL), and the resulting solution was added to the reaction mixture, which as stirred at room temperature for 2 h. The organic solvent was evaporated, the residue was suspended in H_2O (5 mL) and a pH of 1-2 was adjusted (10 % KHSO_4). The aqueous mixture was extracted with ethyl acetate (3 \times 20 mL), the combined organic layers were washed with H_2O (1 \times 15 mL), sat. NaHCO_3 (2 \times 15 mL) and brine (1 \times 15 mL), dried (Na_2SO_4) and evaporated to dryness. The crude product was purified by column chromatography on silica gel with petroleum ether / ethyl acetate (2:1) as eluent to obtain **13** (0.40 g, 34 %) as a colorless solid: mp 82-84 $^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{20} = -3.1$ ($c = 1.81$, MeOH); ^1H NMR (500 MHz, CDCl_3) δ 2.69 (s, 3H, NCH_3), 2.97 (dd, $^2J = 13.1$ Hz, $^3J = 9.0$ Hz, 1H, PhCHHCH). 3.03 (dd, $^2J = 12.9$ Hz, $^3J = 5.7$ Hz, 1H, PhCHHCH), 3.94 (d, $^2J = 17.1$ Hz, 1H, NCHHCN), 4.46 (d, $^2J = 17.1$ Hz, NCHHCN), 4.82-4.89 (m, 1H, NHCHCO), 5.05 (d, $^2J = 12.3$ Hz, 1H, PhCHHO), 5.09 (d, $^2J = 12.3$ Hz, 1H, PhCHHO), 5.59 (d, $^3J = 8.2$ Hz, 1H, NHCHCO), 7.16 (d, $^3J = 6.9$ Hz, 2H, H-2', H-6'), 7.22-7.37 (m, 8H, H_{arom}); ^{13}C NMR (125 MHz, CDCl_3) δ 35.93 (NCH_2CN), 35.36 (NCH_3), 40.02 (PhCH_2CH), 51.93 (NHCHCO), 67.06 (PhCH_2O), 114.40 (NCH_2CN), 127.41 (C-4'), 128.03 (C-2'', C-6''), 128.21 (C-4''), 128.54, 128.84, 129.31 (C-2', C-6', C-3', C-5', C-3'', C-5''), 135.31, 136.11 (C-1', C-1''), 155.58 (OCONH), 172.10 (CHCON); MS (ESI) m/z (rel. intensity) (pos.) 374 (30, $[\text{M} + \text{Na}]^+$), 369 (40, $[\text{M} + \text{NH}_4]^+$), 352 (100, $[\text{M} + \text{H}]^+$), 308 (60, $[\text{M} - \text{CO}_2 + \text{H}]^+$), (neg.) 242 (100, $[\text{M} - \text{BnOH} - \text{H}]^-$), 215 (73, $[\text{M} - \text{BnOH} - \text{HCN} - \text{H}]^-$). Anal. $\text{C}_{20}\text{H}_{21}\text{N}_3\text{O}_3$ (351.40 g/mol) calcd C 68.36, H 6.02, N 11.96; found C 68.64, H 6.11, N 11.73.

***N*-(Benzyloxycarbonyl)-phenylalanyl-methylalanine-nitrile (14)**



Cyanuric chloride (0.20 g, 1.09 mmol) was added to a solution of *N*-(benzyloxycarbonyl)-phenylalanyl-methylalanine-amide (0.43 g, 1.09 mmol) in DMF (10 mL). After stirring for 2 h at room temperature, DMF was evaporated. Ice-cold sat. NaHCO₃ (10 mL) was added and the mixture was extracted with ethyl acetate (4 × 15 mL). The combined organic layers were washed with H₂O (3 × 15 mL) and brine (1 × 15 mL), dried (Na₂SO₄), and the solvent was removed under reduced pressure. The crude product was purified by column chromatography on silica gel with petroleum CH₂Cl₂ / MeOH (20:1) as eluent to obtain **14** (0.35 g, 83 %) as a colorless solid: mp 65-67 °C; [α]_D²⁰ = -19.65 (c = 1.08, MeOH); ¹H NMR (500 MHz, CDCl₃) δ 1.34 (d, ³J = 7.0 Hz, 3H, CHCH₃), 2.65 (s, 1H, PhCHHCH), 2.78 (s, 1H, PhCHHCH), 3.28 (s, 3H, NCH₃), 4.60 (q, ³J = 7.25, 1H, CHCN), 4.92-5.00 (m, 1H, NHCHCO), 5.43-5.47 (m, 2H, PhCH₂O), 7.19-7.35 (m, 10H, H_{arom}), 7.78 (d, ²J = 7.6 Hz, 1H, NHCHCO); ¹³C NMR (125 MHz, CDCl₃) δ 14.21 (CHCH₃), 31.16 (NCH₃), 37.09 (PhCH₂CH), 41.41 (CHCN), 52.63 (NHCHCO), 65.54 (PhCH₂O), 118.71 (CHCN), 126.66 (C-4'), 127.68 (C-4'), 127.88 (C-2'', C-6''), 128.31, 128.43, 129.43 (C-2', C-6', C-3', C-5', C-3'', C-5''), 137.06, 137.21 (C-1', C-1''), 155.91 (OCONH), 171.66 (CHCONH); MS (ESI) *m/z* (rel. intensity) (pos.) 388 (8, [M + Na]⁺), 383 (67, [M + NH₄]⁺), 366 (100, [M + H]⁺), (neg.) 364 (100, [M - H]⁻), 256 (46, [M - BnOH - H]⁻). Anal. C₂₁H₂₃N₃O₃ (365.43 g/mol) calcd C 69.02, H 6.34, N 11.50; found C 68.96, H 6.41, N 11.17.

References

- [1] C. J. Linnevers, M. E. McGrath, R. Armstrong, F. R. Mistry, M. G. Barnes, J. L. Klaus, J. T. Palmer, B. A. Katz, D. Brömme, *Protein Sci.* **1997**, *6*, 919-921.
- [2] R. Löser, K. Schilling, E. Dimmig, M. Gütschow, *J. Med. Chem.* **2005**, *48*, 7688-7707.
- [3] G. Kramer, A. Paul, A. Kreuzsch, S. Schüler, B. Wiederanders, K. Schilling, *Protein Expr. Purif.* **2007**, *54*, 147-156.
- [4] M. K. Edmonds, A. D. Abell, *J. Org. Chem.* **2001**, *66*, 3747-3752.
- [5] G. Verardo, P. Geatti, B. Lesa, *Synthesis* **2005**, 559-564.
- [6] C. Giordano, R. Calabretta, C. Gallina, V. Consalvi, R. Scandurra, *Farmaco* **1991**, *46*, 1497-1516.
- [7] S. Nozaki, I. Muramatsu, *Bull. Chem. Soc. Jpn.* **1988**, *61*, 2647-2648.
- [8] H. T. Hanson, E. L. Smith, *J. Biol. Chem.* **1948**, *175*, 833-848.
- [9] S. M. A. Salam, K.-i. Kagawa, K. Kawashiro, *Tetrahedron: Asymmetry* **2006**, *17*, 22-29.
- [10] R. Pascal, M. Lasperas, J. Taillades, A. Commeyras, A. Perez-Rubalcaba, *Bull. Soc. Chim. Fr.* **1984**, 329-337.